Clinical Trial Update: A Study to Assess Preference for Subcutaneous Trastuzumab Treatment in Participants With Human Epidermal Growth Factor Receptor (HER)2-Positive Metastatic Breast Cancer Responding to First-Line Intravenous Trastuzumab for at Least 3 Years [Phase 3]

View source ↗

Summary

Phase 3 trial updating preference for subcutaneous versus intravenous trastuzumab in HER2-positive metastatic breast cancer patients responding to IV trastuzuma…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• trastuzumab (subcutaneous and intravenous forms) (trastuzumab)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Breast Cancer | Phase 3 | Status: COMPLETED